The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Potential therapeutic implications of cancer stem cells in glioblastoma
Open accessAbstract
Glioblastoma is the most common and lethal type of primary brain tumor. Despite recent therapeutic advances in other cancers, the treatment of glioblastomas remains ineffective and essentially palliative. The treatment failure is a result of a number of causes, but we and others have demonstrated that a highly tumorigenic subpopulation of cancer cells called glioblastoma stem cells (GSCs) display relative resistance to radiation and chemotherapy. GSCs also contribute to tumor growth through the stimulation of angiogenesis, which has been shown to be a useful therapeutic target in the treatment of recurrent or progressive malignant gliomas. Cancer stem cells also have been hypothesized as a contributor to systemic metastases. While glioblastomas rarely metastasize beyond the central nervous system, glioblastomas invade into brain structures to prevent surgical cure and GSCs have an extremely invasive phenotype. Collectively, these studies and others suggest that GSCs may be important therapeutic targets not only to achieve cure but even reduce tumor relapse and improve overall survival. Many recent studies suggest that GSCs share core regulatory pathways with normal embryonic and somatic stem cells, but display important distinctions that provide clues into useful treatment targets. The cancer stem cell hypothesis may also modify our approaches in tumor imaging and biomarker development, but clinical validation waits. In this review, we summarize the current understanding of GSC biology with a focus on potential anti-GSC therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.018 · Cited by 1,354
Self-citationA specialized vascular niche for adult neural stem cells
Tavazoie, M., Van der Veken, L., Silva-Vargas, V., Louissaint, M., Colonna, L., Zaidi, B., Garcia-Verdugo, J. M., & Doetsch, F. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.07.025 · Cited by 1,033
Shen, Q., Wang, Y., Kokovay, E., Lin, G., Chuang, S.-M., Goderie, S. K., Roysam, B., & Temple, S. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.07.026 · Cited by 1,027
Mirzadeh, Z., Merkle, F. T., Soriano-Navarro, M., Garcia-Verdugo, J. M., & Alvarez-Buylla, A. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.07.004 · Cited by 1,015
Silber, J., Lim, D. A., Petritsch, C., Persson, A. I., Maunakea, A. K., Yu, M., Vandenberg, S. R., Ginzinger, D. G., James, C. D., Costello, J. F., et al. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-14 · Cited by 957
Thomas, K. R., & Capecchi, M. R. (1990) · Nature · doi:10.1038/346847a0 · Cited by 896
Heddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9701 · Cited by 813 · cited 3×
“conditions [31,140], we believe that eliminating both GSC and nonGSC cancer cell populations is essential to achieve therapeutic”
Self-citation
Cited by
Yao, Y., Ma, J., Xue, Y., Wang, P., Li, Z., Liu, J., Chen, L., Xi, Z., Teng, H., Wang, Z., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.12.051 · Cited by 338
Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules
Leder, K., Pitter, K., LaPlant, Q., Hambardzumyan, D., Ross, B. D., Chan, T. A., Holland, E. C., & Michor, F. (2014) · Cell · doi:10.1016/j.cell.2013.12.029 · Cited by 267
Targeting adaptive glioblastoma: an overview of proliferation and invasion
Xie, Q., Mittal, S., & Berens, M. E. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou147 · Cited by 262
Biological activity of tumor-treating fields in preclinical glioma models
Silginer, M., Weller, M., Stupp, R., & Roth, P. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.171 · Cited by 111
Comprehensive analysis of microRNA expression profile in malignant glioma tissues
Piwecka, M., Rolle, K., Belter, A., Barciszewska, A. M., Żywicki, M., Michalak, M., Nowak, S., Naskręt-Barciszewska, M. Z., & Barciszewski, J. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.03.007 · Cited by 108
Metadata
- Authors
- Cheng, L., Bao, S., & Rich, J. N.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 80
- Issue
- 5
- Pages
- 654-665
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W1976488065
- Cited by
- 193
- References
- 17
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential therapeutic implications of cancer stem cells in glioblastoma. https://app.cochat.ai/papers/10.1016/j.bcp.2010.04.035
- The paper
- Cheng, L., Bao, S., & Rich, J. N. (2010). Potential therapeutic implications of cancer stem cells in glioblastoma. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2010.04.035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.